A genetic basis for the variable effect of smoking/nicotine on Parkinson's disease

Pharmacogenomics Journal

Volumn 13, Issue 6, 2013, Pages 530-537

  Hill Burns, E M ^a   Singh, N ^a   Ganguly, P ^a   Hamza, T H ^a   Montimurro, J ^a   Kay, D M ^a   Yearout, D ^a   Sheehan, P ^a   Frodey, K ^a   McLear, J A ^a   Feany, M B ^c   Hanes, S D ^a,d,e   Wolfgang, W J ^a,d   Zabetian, C P ^b   Factor, S A ^f   Payami, H ^a,d  

^a WADSWORTH CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d STATE UNIVERSITY OF NEW YORK   (United States)

^e State University of New York Upstate Medical University: College of Medicine   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

nicotine; Parkinson's disease; SV2C

Indexed keywords

CYTOPLASM PROTEIN; DOPAMINE; NICOTINE; PARAQUAT; PROTEIN SV2C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DOPAMINE RELEASE; DROSOPHILA MELANOGASTER; FEMALE; GENE EXPRESSION; GENETIC CODE; GENETIC IDENTIFICATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MALE; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEPLETION; SMOKING; SUBSTANTIA NIGRA; SYNAPSE VESICLE;

ANIMALS; DOPAMINE; DROSOPHILA; GENE EXPRESSION; GENE-ENVIRONMENT INTERACTION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MODELS, BIOLOGICAL; NICOTINE; PARKINSON DISEASE; SMOKING;

EID: 84888138764     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2012.38     Document Type: Article

References (35)

1. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002; 52: 276-284.
2. Powers K, Kay D, Factor S, Zabetian C, Higgins D, Samii A et al. Combined effects of smoking, coffee and NSAIDs on Parkinson's disease risk. Mov Disord 2008; 23: 88-95.
3. Quik M, Parameswaran N, McCallum SE, Bordia T, Bao S, McCormack A et al. Chronic oral nicotine treatment protects against striatal degeneration in MPTPtreated primates. J Neurochem 2006; 98: 1866-1875.
4. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001; 21: RC143.
5. Evans AH, Lawrence AD, Potts J, MacGregor L, Katzenschlager R, Shaw K et al. Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J Neurol Neurosurg Psychiatry 2006; 77: 317-321.
6. Hamza TH, Chen H, Hill-Burns EM, Rhodes SL, Montimurro J, Kay DM et al. Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee. PLoS Genet 2011; 7: e1002237.
7. Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B. Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol 2009; 169: 919-926.
8. Wang A, Costello S, Cockburn M, Zhang X, Bronstein J, Ritz B. Parkinson's disease risk from ambient exposure to pesticides. Eur J Epidemiol 2011; 26: 547-555.
9. Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M et al. Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect 2011; 119: 866-872.
10. Chaudhuri A, Bowling K, Funderburk C, Lawal H, Inamdar A, Wang Z et al. Interaction of genetic and environmental factors in a Drosophila parkinsonism model. J Neurosci 2007; 27: 2457-2467.
11. Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 2010; 42: 781-785.
12. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125(Pt 4): 861-870.
13. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
14. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
15. Payami H, Joe S, Farid NR, Stenszki V, Chan SH, Thomson G. Relative predispositional effects (RPE's) of marker alleles with disease: HLA-DR and autoimmune thyroid disease. Am J Hum Genet 1989; 45: 541-546.
16. Hill-Burns EM, Factor SA, Zabetian CP, Thomson G, Payami H. Evidence for more than one Parkinson's disease-associated variant within the HLA region. PLoS One 2011; 6: e27109.
17. Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SF et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res 2007; 17: 1665-1674.
18. Kaplan E, Meier EL. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958; 53: 457-481.
19. Gentleman R, Carey V, Bates D, Bolstad B, Dettling M, Dudoit S et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
20. Wu Z, Irizarry RA. Preprocessing of oligonucleotide array data. Nat Biotechnol 2004; 22: 656-658.
21. Smyth G. limma: Linear models for microarray data. In: Gentleman R, Carey VJ, Huber W, Irizarry RA, Dudoit S (eds) Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Springer: New York, 2005, pp 397-420.
22. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Statist Soc Ser B 1995; 57: 289-300.
23. Hu Y, Flockhart I, Vinayagam A, Bergwitz C, Berger B, Perrimon N et al. An integrative approach to ortholog prediction for disease-focused and other functional studies. BMC Bioinformatics 2011; 12: 357.
24. Thomas D. Gene-environment-wide association studies: emerging approaches. Nat Rev Genet 2010; 11: 259-272.
25. Turner TJ. Nicotine enhancement of dopamine release by a calcium-dependent increase in the size of the readily releasable pool of synaptic vesicles. J Neurosci 2004; 24: 11328-11336.
26. Esposito G, Ana Clara F, Verstreken P. Synaptic vesicle trafficking and Parkinson's disease. Dev Neurobiol 2012; 72: 134-144.
27. Feany MB, Lee S, Edwards RH, Buckley KM. The synaptic vesicle protein SV2 is a novel type of transmembrane transporter. Cell 1992; 70: 861-867.
28. Dardou D, Dassesse D, Cuvelier L, Deprez T, De Ryck M, Schiffmann SN. Distribution of SV2C mRNA and protein expression in the mouse brain with a particular emphasis on the basal ganglia system. Brain Res 2011; 1367: 130-145.
29. Nowack A, Malarkey EB, Yao J, Bleckert A, Hill J, Bajjalieh SM. Levetiracetam reverses synaptic deficits produced by overexpression of SV2A. PLoS One 2011; 6: e29560.
30. Janz R, Sudhof TC. SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Neuroscience 1999; 94: 1279-1290.
31. Quik M, O'Leary K, Tanner CM. Nicotine and Parkinson's disease: implications for therapy. Mov Disord 2008; 23: 1641-1652.
32. Itti E, Villafane G, Malek Z, Brugieres P, Capacchione D, Itti L et al. Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study. Nucl Med Commun 2009; 30: 513-518.
33. Villafane G, Cesaro P, Rialland A, Baloul S, Azimi S, Bourdet C et al. Chronic high dose transdermal nicotine in Parkinson's disease: an open trial. Eur J Neurol 2007; 14: 1313-1316.
34. Lemay S, Chouinard S, Blanchet P, Masson H, Soland V, Beuter A et al. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 31-39.
35. Vieregge A, Sieberer M, Jacobs H, Hagenah JM, Vieregge P. Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology 2001; 57: 1032-1035.